|
|||||
|
|
Pulmonary mucormycosis in the aftermath of critical COVID-19 in an immunocompromised patient: Mind the diagnostic gap |
|
| Authors: | Cornelia Geisler Crone Jannik Helweg-Larsen Morten Steensen Maiken Cavling Arendrup Marie Helleberg |
| Affiliation: | 1. Centre of Excellence for Health, Immunity and Infections (CHIP), Rigshospitalet, Blegdamsvej 9, Copenhagen 2100, Denmark;2. Department of Infectious Diseases, Rigshospitalet, Copenhagen 2100, Denmark;3. Department of Department of Intensive Care, 2100 Rigshospitalet, Copenhagen, Denmark;4. Unit of Mycology, Statens Serum Institut, Copenhagen 2300, Denmark;5. Department of Clinical Microbiology, Rigshospitalet, Copenhagen 2100, Denmark;6. Department of Clinical Medicine, University of Copenhagen, Copenhagen 2100, Denmark |
| Abstract: | Mucormycosis has recently been recognized as a severe complication of COVID-19 with high fatality rates. We report a fatal case of COVID-19 associated mucormycosis (CAM) in a non-diabetic immunocompromised patient, who was first misdiagnosed and treated for COVID-19 associated aspergillosis (CAPA). The risk factors and initial clinical presentation of CAPA and CAM are similar, but CAM has a more aggressive course and CAPA and CAM are treated differently. Dedicated diagnostic workup is essential to ensure early treatment of CAM with surgical debridement and targeted antifungal therapy. |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ | |